The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s showing significant promise in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to deliver a significant substantial decrease in body size and benefit metabolic function,